SpartaLabs
0
SpartaLabs Research · June 17, 2026

Cagrilintide: A Research Overview

A research-library overview of cagrilintide — chemistry, amylin receptor pharmacology, regulatory milestones, and development history. Educational reference.

cagrilintideamylinamylin-analogcalcitonin-receptorcagrinsema

Introduction

Cagrilintide (development code AM833) is a synthetic, long-acting acylated analog of the human peptide hormone amylin, developed by Novo Nordisk. The compound belongs to the amylin receptor agonist pharmacological class and was designed to address a key pharmacokinetic limitation of the only previously approved amylin analog — pramlintide — by enabling extended-interval, once-weekly dosing. Scientific interest in cagrilintide has centered on its receptor binding profile, its combination with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide under the designation CagriSema, and the structural pharmacology that distinguishes it from earlier amylin analogs.

Background

Amylin (also known as islet amyloid polypeptide, IAPP) is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to nutrient intake. The hormone was isolated and characterized by Cooper and colleagues in 1987 from amyloid-rich pancreatic deposits of individuals with type 2 diabetes [1]. Subsequent research established that amylin signals through a family of heterodimeric G protein-coupled receptors formed by the calcitonin receptor (CTR) and one of three receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3), yielding the AMY1, AMY2, and AMY3 receptor subtypes, respectively [2].

Pramlintide, approved by the United States Food and Drug Administration (FDA) in 2005 under the brand name Symlin, demonstrated that pharmacological amylin receptor activation could produce clinically meaningful outcomes in the context of insulin-dependent diabetes [3]. The molecule's plasma half-life of approximately 50 minutes necessitated multiple daily administrations, and this pharmacokinetic constraint motivated the search for structurally modified, long-acting amylin analogs capable of once-weekly dosing. Cagrilintide emerged from that search as the first analog to achieve the target pharmacokinetic profile.

Chemistry and Structure

Cagrilintide is a 36-amino acid acylated peptide. Its backbone was derived from the human amylin sequence with modifications informed by the calcitonin peptide family, including a proline substitution at position 37 (P37) that abolishes the amyloidogenic tendency of native amylin — the structural property that makes the wild-type peptide unsuitable for concentrated pharmaceutical formulations [4].

The defining structural feature of cagrilintide is an N-terminal C20 fatty acid moiety attached via a linker to the peptide scaffold. This acylation strategy facilitates reversible non-covalent binding to serum albumin in circulation, substantially reducing renal clearance and proteolytic degradation rates compared to native amylin or pramlintide. The resulting plasma half-life of approximately 160–180 hours is consistent with once-weekly dosing [4]. This albumin-binding strategy is structurally analogous to that employed in semaglutide, though the two compounds differ substantially in their receptor targets, peptide backbone sequences, and physiological signaling profiles.

The development chemistry leading to the selection of cagrilintide as a clinical candidate was reported by Andreassen and colleagues (2021) in the Journal of Medicinal Chemistry, describing structure-activity relationship work that evaluated multiple lipidated amylin analogs and identified the compound's preclinical profile as suitable for clinical advancement [4].

Pharmacological Classification

Cagrilintide is classified as a long-acting amylin receptor agonist. Published structural and pharmacological studies have characterized it as a non-selective agonist at the calcitonin receptor (CTR) and at the AMY1, AMY2, and AMY3 receptor subtypes [5]. This receptor profile distinguishes cagrilintide from pramlintide, which shows more restricted selectivity, and from salmon calcitonin, which carries a different receptor activation and signaling signature.

A 2025 study published in eBioMedicine examined the receptor subtype dependency of cagrilintide's pharmacological activity in vivo, reporting that body weight effects in mouse models were mediated principally through AMY1R and AMY3R in the brain rather than through CTR alone [6]. These findings indicated that RAMP1 and RAMP3 — the defining accessory subunits of AMY1R and AMY3R — are required for cagrilintide's characteristic in vivo potency profile and differentiate it pharmacologically from calcitonin-class peptides.

Cagrilintide is placed within the broader calcitonin peptide family, alongside amylin and calcitonin, but is distinguished as an amylin-biased agonist by its receptor activation profile across the AMY1–3 and CTR landscape.

Regulatory Status

In December 2025, Novo Nordisk submitted a New Drug Application (NDA) to the FDA for CagriSema — a fixed-dose, once-weekly combination of cagrilintide and semaglutide — for chronic weight management in adults, based on Phase 3 REDEFINE clinical program data [7]. This submission marked the first regulatory filing for a fixed-dose combination of a GLP-1 receptor agonist and an amylin receptor agonist in the United States.

Separately, Phase 3 monotherapy data presented in September 2025 reported clinically meaningful weight reductions for cagrilintide as a single agent compared to placebo, leading Novo Nordisk to initiate a dedicated Phase 3 monotherapy program designated RENEW [8]. Both the CagriSema NDA review and the RENEW program represent active regulatory and clinical milestones as of the date of this article.

Discovery History

The discovery of cagrilintide follows directly from the history of amylin pharmacology. Following the initial characterization of amylin in 1987 [1], researchers identified a pharmacologically active rat amylin analog and later developed pramlintide as the first clinically viable amylin mimetic. The structural tendency of human amylin to form amyloid fibrils at pharmaceutical concentrations posed formulation challenges that were resolved in pramlintide through rat-sequence substitutions, providing proof of concept for the amylin receptor agonist class.

Novo Nordisk scientists undertook a medicinal chemistry campaign beginning in the early 2010s with the objective of creating a fully human-amylin-informed analog that could: (1) resist amyloidogenesis in formulation, (2) achieve albumin-mediated half-life extension through acylation, and (3) retain potent amylin receptor agonism. The structural and activity data from this program were disclosed in 2021 [4], establishing the scientific basis for the selection of cagrilintide as the first amylin analog with a pharmacokinetic profile suitable for once-weekly dosing.

First-in-human clinical investigation of cagrilintide in combination with semaglutide was reported in a Phase 1b trial published in The Lancet in 2021, which described the safety, tolerability, and pharmacokinetic profile of the compound across multiple dose levels [9]. Detailed sourcing, purity specifications, and certificate of analysis documentation for research-grade material are covered in the cagrilintide sourcing and quality article. Research-grade cagrilintide from SpartaLabs is verified by third-party HPLC and mass spectrometry analysis.

References

  1. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA. 1987;84(23):8628–8632. PMID: 3320585.

  2. Hay DL, Christopoulos G, Christopoulos A, Sexton PM. Amylin receptors: molecular composition and pharmacology. Biochem Soc Trans. 2004;32(5):865–867. PMID: 15494035. DOI: 10.1042/BST0320865

  3. US Food and Drug Administration. SYMLIN (pramlintide acetate) injection: NDA 021332 approval. 2005. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021332lbl.pdf

  4. Andreassen KV, Feigh M, Hjuler ST, Christoffersen BØ, Damgaard Møller A, Rolin B, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64(15):11183–11194. DOI: 10.1021/acs.jmedchem.1c00565

  5. Deganutti G, Atanasio S, Bhatt DL, Igonet S, Koehl A, Bhattacharya S, et al. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nat Commun. 2025;16:3389. PMID: 40204768. DOI: 10.1038/s41467-025-58680-y

  6. Carvas AO, Leuthardt A, Kulka P, Lommi G, Hassan S, Coester B, et al. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. eBioMedicine. 2025;105836. PMC12270663. DOI: 10.1016/j.ebiom.2025.105836

  7. Novo Nordisk. Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management. Press release. December 2025. Available at: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916470

  8. Novo Nordisk. Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme. Press release. September 2025. Available at: https://www.globenewswire.com/news-release/2025/09/16/3150597/0/en/novo-nordisk-presents-phase-3-data-for-next-generation-amylin-cagrilintide-leading-to-advancement-into-dedicated-clinical-programme.html

  9. Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10288):1736–1748. PMID: 33894838. DOI: 10.1016/S0140-6736(21)00845-X

Frequently asked questions

  • What is cagrilintide?

    Cagrilintide (development code AM833) is a synthetic, long-acting acylated analog of the human peptide hormone amylin, developed by Novo Nordisk. It belongs to the amylin receptor agonist pharmacological class and was designed to enable once-weekly dosing — addressing a key limitation of the earlier amylin analog pramlintide, which required multiple daily administrations.

  • What is the chemical structure of cagrilintide?

    Cagrilintide is a 36-amino acid acylated peptide. Its backbone is derived from the human amylin sequence with a proline substitution at position 37 (P37) to prevent amyloid fibril formation, and an N-terminal C20 fatty acid moiety attached via a linker to facilitate reversible albumin binding. The resulting plasma half-life of approximately 160–180 hours is consistent with once-weekly dosing.

  • What receptors does cagrilintide target?

    Cagrilintide is a non-selective agonist at the calcitonin receptor (CTR) and at the AMY1, AMY2, and AMY3 receptor subtypes — heterodimeric G protein-coupled receptors formed by CTR in complex with RAMP1, RAMP2, or RAMP3. A 2025 study reported that body weight effects in mouse models were mediated principally through AMY1R and AMY3R in the brain.

  • Is cagrilintide FDA approved?

    As of the date of this article, cagrilintide is not individually FDA approved. In December 2025, Novo Nordisk submitted a New Drug Application for CagriSema — a fixed-dose combination of cagrilintide and semaglutide — for chronic weight management in adults, based on Phase 3 REDEFINE clinical program data. That NDA review was ongoing.

  • Who developed cagrilintide?

    Cagrilintide was developed by Novo Nordisk through a systematic medicinal chemistry campaign begun in the early 2010s. The compound's scientific basis was first publicly disclosed by Andreassen and colleagues in the Journal of Medicinal Chemistry in 2021, and first-in-human pharmacokinetic data were reported by Enebo and colleagues in The Lancet in the same year.